This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Diabetes; metabolic disorders	Protein kinase C δ (PRKCD)	Patient sample and mouse studies suggest inhibiting PRKCD could help prevent metabolic syndrome and type 2 diabetes. In hepatic tissue samples from obese subjects with and without diabetes, PRKCD expression was greater than that in samples from lean controls. In mice, whole-body or liver-specific inactivation of <i>Prkcd</i> increased insulin sensitivity and glucose tolerance compared with those in wild-type controls. Next steps could include identifying and evaluating specific PRKCD inhibitors in the mouse models. SciBX 4(22); doi:10.1038/scibx.2011.635 Published online June 2, 2011	Patent and licensing status unavailable	Bezy, O. <i>et al. J. Clin. Invest.</i>; published online May 16, 2011; doi:10.1172/JCI46045 Contact: C. Ronald Kahn, Joslin Diabetes Center and Harvard Medical School, Boston, Mass. e-mail: c.ronald.kahn@joslin.harvard.edu